The "true human" antibodies (antibodies derived without modification from humans who possess natural immunity to certain diseases) targeting SARS-CoV-2 were found to effectively neutralize the virus at concentrations around four times better than other antibodies under consideration from the U.S. Food and Drug Administration for emergency use authorization. The company's therapeutic cocktail also targets influenza. The unique combination of targeting both SARS-CoV-2 and all known strains of influenza could provide the company with a uniquely effective therapy for treating complex infections from one or more viruses.

The Fluvid candidate therapy was developed by XBiotech by incorporating influenza true human antibodies that have been evaluated for their ability to target all known strains of influenza viruses with true human COVID-19 antibodies that are derived from patients who recovered rapidly with potent neutralizing antibodies against the virus.

The company's Fluvid candidate targets seasonal H1N1 and H3N2 strains; pandemic strains H1N1, H2N2, H3N2; avian influenza strains H5N1, H5N2 and H7N9; and even H9N2 and H10N8 (found in poultry).

Abpro's neutralizing COVID-19 mAb shows efficacy in monkeys
Abpro has published preclinical data in a Nature Communications article demonstrating the prophylactic and therapeutic production of neutralizing...

Synthetic nanobodies show potential for new COVID-19 therapies
Synthetic nanobodies may provide a practical avenue for the development of novel COVID-19 therapies compared to human antibodies, which are bulkier and...